SCHEMBL24263175

SCHEMBL24263175

COCC1OC1CCc1cc(F)ccc1OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 6/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
SLC6A2 P23975 6/20 0.41
SLC6A4 P31645 6/20 0.41
SLC6A3 Q01959 6/20 0.41
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
HTR1A P08908 2/20 0.41
DRD2 P14416 2/20 0.41
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KDM4E B2RXH2 1/20 0.39
NPY1R P25929 1/20 0.39
HTT P42858 1/20 0.39
NPY2R P49146 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20175293 0.88 ABCB1 (0.43) ABCB1ABCG2SLC6A2SLC6A4SLC6A3
SCHEMBL20175291 0.88 ABCB1 (0.43) ABCB1ABCG2SLC6A2SLC6A4SLC6A3
SCHEMBL19988033 0.86 HTR1A (0.43) ABCB1ABCG2SLC6A2SLC6A4SLC6A3
SCHEMBL19988040 0.86 HTR1A (0.43) ABCB1ABCG2SLC6A2SLC6A4SLC6A3
SCHEMBL19988048 0.86 HTR1A (0.43) ABCB1ABCG2SLC6A2SLC6A4SLC6A3
SCHEMBL19988032 0.86 HTR1A (0.43) ABCB1ABCG2SLC6A2SLC6A4SLC6A3
SCHEMBL19988037 0.86 HTR1A (0.43) ABCB1ABCG2SLC6A2SLC6A4SLC6A3
SCHEMBL24263357 0.79 SLC6A2 (0.48) ABCB1ABCG2SLC6A2SLC6A4SLC6A3
SCHEMBL16797594 0.76 HTR1A (0.53) ABCB1ABCG2FFAR1FFAR4HTR1A
SCHEMBL23940700 0.76 SLC6A2 (0.45) ABCB1ABCG2SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220056003-A1 NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2022-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220056003-A1 NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF CYP4A11, CYP11B2, CYP11B1 ABCB1 2021/4885ABCG2 2721/4885SLC6A2 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.